References - Haematology

·  ^ {"Mollison’s Blood Transfusion in Clinical Medicine" by H.Klein, D. Anstee (2005), p.406
^ {"Vicars of Christ" - Peter de Rossa}
·  ^ Bernice Glatzer Rosenthal. New Myth, New World: From Nietzsche to Stalinism, Pennsylvania State University, 2002, ISBN 0-271-02533-6 pp. 161-162.

·  ^ Laura Landro (2007-01-10). "New rules may shrink ranks of blood donors". Wall Street Journal. http://www.post-gazette.com/pg/07010/752655-28.stm. 

·  ^ editor, Bjorn Magne Eggen. (1998). Standards for Blood Banks and Transfusion Services, 18th ed. American Association of Blood Banks, Bethesda, MD.. American Association of Blood Banks. ISBN 380556659X. 

·  ^ "Testing of Donor Blood for Infectious Diseases". American Association of Blood Banks. 2006-08/14. http://www.aabb.org/Content/About_Blood/Facts_About_Blood_and_Blood_Banking/fabloodtesting.htm. 

·  ^ Ratko TA; Cummings JP; Oberman HA; Crookston KP; DeChristopher PJ; Eastlund DT; Godwin JE; Sacher RA; Yawn DH; Matuszewski KA (2001 Oct). "Evidence-based recommendations for the use of WBC-reduced cellular blood components". Transfusion 41 (10): 1310–9. doi:10.1046/j.1537-2995.2001.41101310.x. PMID 11606834. 

·  ^ Goes EG; Borges JC; Covas DT; Orellana MD; Palma PV; Morais FR; Pela CA. Transfusion (2006 Jan). Quality control of blood irradiation: determination T cells radiosensitivity to cobalt-60 gamma rays. 46. pp. 34–40. PMID 16398728. 

·  ^ Circular of information for the use of human blood and blood components: AABB

·  ^ "Red blood cell transfusions in newborn infants: Revised guidelines". Canadian Paediatric Society (CPS). http://www.cps.ca/english/statements/fn/fn02-02.htm#What%20type%20of%20RBCs%20should%20be%20used. Retrieved on 2007-02-02. 

·  ^ KM Radhakrishnan , Srikumar Chakravarthi , S Pushkala, J Jayaraju (2003 Aug). "Component therapy". Indian J Pediatr 70 (8): 661–6. doi:10.1007/BF02724257. PMID 14510088. 

·  ^ Blood Processing. University of Utah. Available at: http://library.med.utah.edu/WebPath/TUTORIAL/BLDBANK/BBPROC.html. Accessed on: December 15, 2006.

·  ^ D. Harmening, Modern Blood Banking and Transfusion Practices, 4th Ed. 1999

·  ^ Blajchman M (2007). "Incidence and significance of the bacterial contamination of blood components". Dev Biol (Basel) 108: 59–67. doi:10.2478/v10036-007-0007-1. PMID 12220143. 

·  ^ Silliman C, Paterson A, Dickey W, Stroneck D, Popovsky M, Caldwell S, Ambruso D (1997). "The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study". Transfusion 37 (7): 719–26. doi:10.1046/j.1537-2995.1997.37797369448.x. PMID 9225936. 

·  ^ Popovsky M, Chaplin H, Moore S (1992). "Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy". Transfusion 32 (6): 589–92. doi:10.1046/j.1537-2995.1992.32692367207.x. PMID 1502715. 

·  ^ Liu QP, Sulzenbacher G, Yuan H, Bennett EP, Pietz G, Saunders K, Spence J, Nudelman E, Levery SB, White T, Neveu JM, Lane WS, Bourne Y, Olsson ML, Henrissat B, Clausen H (2007). "Bacterial glycosidases for the production of universal red blood cells". Nat Biotechnol 25: 454. doi:10.1038/nbt1298. PMID 17401360. 

·  ^ "Blood groups 'can be converted'". BBC news. 2007-04-02. http://news.bbc.co.uk/1/hi/health/6517137.stm.

^ Warhurst DC, Williams JE (1996). "Laboratory diagnosis of malaria". J Clin Pathol 49: 533–38. doi:10.1136/jcp.49.7.533. PMID 8813948. 
http://www.nlm.nih.gov/medlineplus/spleendiseases.html
http://www.merck.com/mmhe/sec14/ch179/ch179a.html
^ Spleen, Internet Encyclopedia of Science
^ Brender, MD, Erin; Allison Burke, MA, illustrator, Richard M. Glass, MD, editor (2005-11-23). "Spleen Patient Page" (PDF). Journal of the American Medical Association (American Medical Association) 294 (20): 2660. http://jama.ama-assn.org/cgi/reprint/294/20/2660.pdf. Retrieved on 2008-03-20. 
^ Spielmann, Audrey L.; David M. DeLong, Mark A. Kliewer (01 Jan 2005). "Sonographic Evaluation of Spleen Size in Tall Healthy Athletes". American Journal of Roentgenology (American Roentgen Ray Society) 2005 (184): 45–49. PMID 15615949. http://www.ajronline.org/cgi/content/abstract/184/1/45. Retrieved on 2008-09-09. 
^ thefreedictionary.com - penicilliary radicles
^ Vellguth, Swantje; Brita von Gaudecker, Hans-Konrad Müller-Hermelink. "The development of the human spleen". Cell and Tissue Research (Springer Berlin / Heidelberg) 242 (3): 579–592. http://www.springerlink.com/content/q231303t1455j524/. Retrieved on 2009-02-14. 
^ Carey, Bjorn (May 5, 2006). "Horse science: What makes a Derby winner - Spleen acts as a 'natural blood doper,' scientist says". MSNBC.com (Microsoft). http://www.msnbc.msn.com/id/12648465/. Retrieved on 2006-05-09. 
^ Robertson's Word Pictures of the New Testament, commentary on 1 Peter 3:8
·  ^ thrombolysis at Dorland's Medical Dictionary

·  ^ Wardlaw JM, Zoppo G, Yamaguchi T, Berge E (2003). "Thrombolysis for acute ischaemic stroke". Cochrane database of systematic reviews (Online) (3): CD000213. doi:10.1002/14651858.CD000213. PMID 12917889.

^ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0721629210.
^ Freedberg, et. al. (2003). Fitzpatrick's Dermatology in General Medicine. (6th ed.). McGraw-Hill. ISBN 0071380760.
^ Kumar, Robbins and Cotran: Pathologic Basis of Disease, 7th ed., 2005. Saunders.
·  ^ Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M (1974). "Biologic and clinical significance of cryoglobulins. A report of 86 cases". Am. J. Med. 57 (5): 775–88. doi:10.1016/0002-9343(74)90852-3. PMID 4216269. 

·  ^ a b Ferri C, Zignego AL, Pileri SA (2002). "Cryoglobulins". J. Clin. Pathol. 55 (1): 4–13. PMID 11825916. 

·  ^ a b c d Tedeschi A, Baratè C, Minola E, Morra E (2007). "Cryoglobulinemia". Blood Rev. 21 (4): 183–200. doi:10.1016/j.blre.2006.12.002. PMID 17289231. http://linkinghub.elsevier.com/retrieve/pii/S0268-960X(06)00076-2. 

·  ^ Tissot JD, Schifferli JA, Hochstrasser DF, et al (1994). "Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide". J. Immunol. Methods 173 (1): 63–75. doi:10.1016/0022-1759(94)90284-4. PMID 8034987. 

·  ^ Pascual M, Perrin L, Giostra E, Schifferli JA (1990). "Hepatitis C virus in patients with cryoglobulinemia type II". J. Infect. Dis. 162 (2): 569–70. PMID 2115556.

^ Erowid.org, chemicals, amphetamines, amphetamines_effects
·  ^ "Platelet count aka thrombocyte count". Lab Tests Online UK. 2004-05-28. http://www.labtestsonline.org.uk/understanding/analytes/platelet/test.html. Retrieved on 2008-05-22. 

·  ^ Correia MC, Domingues AL, Lacerda HR, et al (December 2008). "Platelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoni". Trans. R. Soc. Trop. Med. Hyg.. doi:10.1016/j.trstmh.2008.11.017. PMID 19118853. http://linkinghub.elsevier.com/retrieve/pii/S0035-9203(08)00526-9. 

·  ^ Cheung RC, McAuley RJ, Pollard JB (May 2005). "High mortality rate in patients with advanced liver disease independent of exposure to general anesthesia". J Clin Anesth 17 (3): 172–6. doi:10.1016/j.jclinane.2004.06.016. PMID 15896582. http://linkinghub.elsevier.com/retrieve/pii/S0952-8180(05)00051-6. 

·  ^ Scaradavou A (March 2002). "HIV-related thrombocytopenia". Blood Rev. 16 (1): 73–6. doi:10.1054/blre.2001.0188. PMID 11914001. http://linkinghub.elsevier.com/retrieve/pii/S0268960X01901882. 

·  ^ The Annals of Pharmacotherapy, Pantoprazole-Induced Thrombocytopenia. http://www.theannals.com/cgi/content/abstract/40/4/758. 

·  ^ "moon.ouhsc.edu". http://moon.ouhsc.edu/jgeorge/drug%20ITP_single04.htm+. 

·  ^ Furlan M, Lämmle B (2001). "Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease". Best Pract Res Clin Haematol 14 (2): 437–54. doi:10.1053/beha.2001.0142. PMID 11686108. 

·  ^ Tsai H (2003). "Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura". J Am Soc Nephrol 14 (4): 1072–81. doi:10.1097/01.ASN.0000060805.04118.4C. PMID 12660343. 

·  ^ Bussel J, Kuter D, George J, McMillan R, Aledort L, Conklin G, Lichtin A, Lyons R, Nieva J, Wasser J, Wiznitzer I, Kelly R, Chen C, Nichol J (2006). "AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP". N Engl J Med 355 (16): 1672–81. doi:10.1056/NEJMoa054626. PMID 17050891. 

·  ^ AMGEN (2008-03-12). "Press release: Amgen Statement on Successful Outcome of Romiplostim Panel Meeting". Business Wire via drugs.com. http://www.drugs.com/nda/romiplostim_080313.html. Retrieved on 2008-05-22. 

·  ^ "US FDA panel backs Amgen's Nplate against ITP". Reuters. 2008-03-12. http://www.reuters.com/article/rbssHealthcareNews/idUSWAT00911720080312. Retrieved on 2008-05-22.

http://en.wikipedia.org/wiki/Hepatomegaly

^ Grover SA, Barkun AN, Sackett DL (1993). "The rational clinical examination. Does this patient have splenomegaly?". JAMA 270 (18): 2218–21. doi:10.1001/jama.270.18.2218. PMID 8411607.  Ovid full text
http://en.wikipedia.org/wiki/Hepatosplenomegaly

·  ^ eMedicine - Anemia, Chronic : Article by Fredrick M Abrahamian, DO, FACEP

·  ^ eMedicineHealth > anemia article Author: Saimak T. Nabili, MD, MPH. Editor: Melissa Conrad Stöppler, MD. Last Editorial Review: 12/9/2008. Retrieved on 4 April, 2009

·  ^ World Health Organization (2008). Worldwide prevalence of anaemia 1993-2005. Geneva: World Health Organization. ISBN 9789241596657. http://whqlibdoc.who.int/publications/2008/9789241596657_eng.pdf. Retrieved on 25-03-2009. 

·  ^ Recommendations to Prevent and Control Iron Deficiency in the United States MMWR 1998;47 (No. RR-3) p. 5

·  ^ Iron Deficiency Anaemia: Assessment, Prevention, and Control: A guide for programme managers

·  ^ eMedicine - Vitamin B-12 Associated Neurological Diseases : Article by Niranjan N Singh, MD, DM, DNB July 18, 2006

·  ^ Physiology or Medicine 1934 - Presentation Speech

·  ^ Dorlands Medical Dictionary

·  ^ Onions are Toxic to Cats

·  ^ Hébert PC, Wells G, Blajchman MA, et al (1999). "A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group". N. Engl. J. Med. 340 (6): 409–17. PMID 9971864. 

·  ^ Bush RL, Pevec WC, Holcroft JW (1997). "A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients". Am. J. Surg. 174 (2): 143–8. doi:10.1016/S0002-9610(97)00073-1. PMID 9293831. 

·  ^ Bracey AW, Radovancevic R, Riggs SA, et al (1999). "Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome". Transfusion 39 (10): 1070–7. doi:10.1046/j.1537-2995.1999.39101070.x. PMID 10532600. 

·  ^ McIntyre LA, Fergusson DA, Hutchison JS, et al (2006). "Effect of a liberal versus restrictive transfusion strategy on mortality in patients with moderate to severe head injury". Neurocritical care 5 (1): 4–9. doi:10.1385/NCC:5:1:4. PMID 16960287. 

·  ^ Corwin HL, Gettinger A, Pearl RG, et al (2004). "The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States". Crit. Care Med. 32 (1): 39–52. doi:10.1097/01.CCM.0000104112.34142.79. PMID 14707558. 

·  ^ Vincent JL, Baron JF, Reinhart K, et al (2002). "Anemia and blood transfusion in critically ill patients". JAMA 288 (12): 1499–507. doi:10.1001/jama.288.12.1499. PMID 12243637. 

·  ^ a b c Undersea and Hyperbaric Medical Society. "Exceptional Blood Loss - Anemia". http://www.uhms.org/ResourceLibrary/Indications/ExceptionalBloodLossAnemia/tabid/277/Default.aspx. Retrieved on 2008-05-19. 

·  ^ Hart GB, Lennon PA, Strauss MB. (1987). "Hyperbaric oxygen in exceptional acute blood-loss anemia". J. Hyperbaric Med 2 (4): 205–210. http://archive.rubicon-foundation.org/4352. Retrieved on 2008-05-19. 

·  ^ Van Meter KW (2005). "A systematic review of the application of hyperbaric oxygen in the treatment of severe anemia: an evidence-based approach". Undersea Hyperb Med 32 (1): 61–83. PMID 15796315. http://archive.rubicon-foundation.org/4038. Retrieved on 2008-05-19.

http://en.wikipedia.org/wiki/Bleeding_diathesis

http://en.wikipedia.org/wiki/Coagulopathy

·  ^ ""Hairy" Cells in Blood in Lymphoreticular Neoplastic Disease and "Flagellated" Cells of Normal Lymph Nodes -- SCHREK and DONNELLY 27 (2): 199 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/abstract/27/2/199. Retrieved on 2007-09-10. 

·  ^ "American Journal of Clinical Pathology". http://ajcp.metapress.com/link.asp?id=8qytyq1clqmhq9cl. Retrieved on 2009-01-31. 

·  ^ "A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients -- Sainati et al. 76 (1): 157 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/abstract/76/1/157. Retrieved on 2007-09-10. 

·  ^ Cawley JC, Burns GF, Hayhoe FG (1980). "A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia". Leuk. Res. 4 (6): 547–59. doi:10.1016/0145-2126(80)90066-1. PMID 7206776. 

·  ^ a b c d Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D (2001). "The natural history and clinico-pathological features of the variant form of hairy cell leukemia". Leukemia 15 (1): 184–6. doi:10.1038/sj.leu.2401999. PMID 11243388. 

·  ^ Ya-In C, Brandwein J, Pantalony D, Chang H (2005). "Hairy cell leukemia variant with features of intrasinusoidal bone marrow involvement". Arch. Pathol. Lab. Med. 129 (3): 395–8. PMID 15737038. 

·  ^ "The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells -- Burthem and Cawley 83 (2): 497 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/abstract/83/2/497. Retrieved on 2007-09-10. 

·  ^ "Phenotypic analysis of hairy cell leukemia: "variant" cases express the interleukin-2 receptor beta chain, but not the alpha chain (CD25) -- de Totero et al. 82 (2): 528 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/abstract/82/2/528. Retrieved on 2007-09-10. 

·  ^ "A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients -- Sainati et al. 76 (1): 157 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/abstract/76/1/157. Retrieved on 2007-09-10. 

·  ^ Matutes E, Wotherspoon A, Catovsky D (2003). "The variant form of hairy-cell leukaemia". Best Pract Res Clin Haematol 16 (1): 41–56. doi:10.1016/S1521-6926(02)00086-5. PMID 12670464. 

·  ^ Vallianatou K, Brito-Babapulle V, Matutes E, Atkinson S, Catovsky D (1999). "p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant". Leuk. Res. 23 (11): 1041–5. doi:10.1016/S0145-2126(99)00127-7. PMID 10576509. 

·  ^ Miyazaki M, Taguchi A, Sakuragi S, Mitani N, Matsuda K, Shinohara K (May 2004). "[Hairy cell leukemia, Japanese variant, successfully treated with cladribine]" (in Japanese). Rinsho Ketsueki 45 (5): 405–7. PMID 15199752. 

·  ^ "Hairy Cell Leukemia Treatment - National Cancer Institute". http://www.cancer.gov/cancerinfo/pdq/treatment/hairy-cell-leukemia/patient#Keypoint3. Retrieved on 2007-09-07. 

·  ^ Zuzel M, Cawley JC, Paton RC, Burns GF, McNicol GP (1979). "Platelet function in hairy-cell leukaemia". J. Clin. Pathol. 32 (8): 814–21. doi:10.1136/jcp.32.8.814. PMID 512041. 

·  ^ "wiley.com". http://www3.interscience.wiley.com/cgi-bin/abstract/50446/ABSTRACT?CRETRY=1&SRETRY=0. Retrieved on 2007-09-07. 

·  ^ "Mechanisms behind hypocholesterolaemia in hairy cell leukaemia -- Juliusson et al. 311 (6996): 27 -- BMJ". http://www.bmj.com/cgi/content/full/311/6996/27. Retrieved on 2007-09-07. 

·  ^ Clavel J, Mandereau L, Cordier S, et al (1995). "Hairy cell leukaemia, occupation, and smoking". Br. J. Haematol. 91 (1): 154–61. doi:10.1111/j.1365-2141.1995.tb05261.x. PMID 7577624. 

·  ^ Orlandi G, Fanucchi S, Strata G, et al (2000). "Transient autonomic nervous system dysfunction during hyperacute stroke". Acta Neurol. Scand. 102 (5): 317–21. doi:10.1034/j.1600-0404.2000.102005317.x. PMID 11083509. 

·  ^ a b c d e f g h i j k l m n o p q r s Wintrobe, Maxwell Myer (2004). Wintrobe's clinical hematology. John G. Greer; John Foerster, John N. Lukens, George M Rodgers, Frixos Paraskevas (11 ed.). Hagerstown, MD: Lippincott Williams & Wilkins. pp. 2465–2466. ISBN 0-7817-3650-1. 

·  ^ "Clinical Flow Cytometry Case #54". http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2&caseID=54. Retrieved on 2007-09-07. 

·  ^ Cannon T, Mobarek D, Wegge J, Tabbara IA (October 2008). "Hairy cell leukemia: current concepts". Cancer Invest. 26 (8): 860–5. doi:10.1080/07357900801965034. PMID 18798068. http://www.informaworld.com/openurl?genre=article&doi=10.1080/07357900801965034&magic=pubmed||1B69BA326FFE69C3F0A8F227DF8201D0. 

·  ^ "theoncologist.alphamedpress.org". http://theoncologist.alphamedpress.org/content/vol11/issue7/images/large/780tbl4.jpeg. Retrieved on 2007-09-07. 

·  ^ "eMedicine - Hairy Cell Leukemia : Article by Emmanuel C Besa". http://www.emedicine.com/med/topic937.htm#section~Differentials. Retrieved on 2008-03-15. 

·  ^ Wanko SO, de Castro C (2006). "Hairy cell leukemia: an elusive but treatable disease". Oncologist 11 (7): 780–9. doi:10.1634/theoncologist.11-7-780. PMID 16880237. http://theoncologist.alphamedpress.org/cgi/pmidlookup?view=long&pmid=16880237. 

·  ^ "Hairy Cell Leukemia: An Elusive but Treatable Disease -- Wanko and de Castro 11 (7): 780 -- The Oncologist". http://theoncologist.alphamedpress.org/cgi/content/full/11/7/780. Retrieved on 2007-09-10. 

·  ^ "Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature -- Vanhentenrijk et al. 104 (1): 250 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;104/1/250. Retrieved on 2007-09-10. 

·  ^ "Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial -- Robak et al. 109 (9): 3672 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;109/9/3672. Retrieved on 2007-09-10. 

·  ^ Else M, Ruchlemer R, Osuji N, et al (2005). "Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years". Cancer 104 (11): 2442–8. doi:10.1002/cncr.21447. PMID 16245328. 

·  ^ "Rituximab in relapsed or refractory hairy cell leukemia -- Thomas et al. 102 (12): 3906 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/abstract/102/12/3906. Retrieved on 2007-09-10. 

·  ^ "Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia -- Nieva et al. 102 (3): 810 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/full/102/3/810. Retrieved on 2007-09-10. 

·  ^ "Successful treatment of hairy cell leukemia variant with rituximab - Leukemia and Lymphoma". http://www.informaworld.com/smpp/content?content=10.1080/10428190500083433. Retrieved on 2007-09-10. 

·  ^ "eMedicine - Hairy Cell Leukemia : Article by Emmanuel C Besa, MD". http://www.emedicine.com/med/topic937.htm#section~medication. Retrieved on 2007-09-10. 

·  ^ "NEJM -- Alpha interferon for induction of remission in hairy-cell leukemia". http://content.nejm.org/cgi/content/abstract/310/1/15. Retrieved on 2007-09-10. 

·  ^ a b Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985). "Treatment of hairy cell leukemia with recombinant alpha 2 interferon". Blood 65 (3): 644–8. PMID 3971043. 

·  ^ a b Baker PK, PettittAR, Slupsky JR, et al (2002). "Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion". Blood 100 (2): 647–53. doi:10.1182/blood.V100.2.647. PMID 12091360. 

·  ^ ClinicalTrials.gov NCT00074048

·  ^ ClinicalTrials.gov NCT00462189

·  ^ ClinicalTrials.gov NCT00337311

·  ^ "Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia -- Saven et al. 93 (8): 2471 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/full/93/8/2471. Retrieved on 2007-09-10. 

·  ^ "Second Malignancies in Patients With Hairy Cell Leukemia in British Columbia: A 20-Year Experience -- Au et al. 92 (4): 1160 -- Blood". http://bloodjournal.hematologylibrary.org/cgi/content/abstract/92/4/1160. Retrieved on 2007-09-10. 

·  ^ "Hairy cell leukemia". http://www.pennhealth.com/ency/article/000592.htm. Retrieved on 2007-09-07. 

·  ^ Yetgin S, Olcay L, Yenicesu I, Oner AF, Cağlar M (September 2001). "Relapse in hairy cell leukemia due to isolated nodular skin infiltration". Pediatr Hematol Oncol 18 (6): 415–7. doi:10.1080/088800101316922047. PMID 11554237. http://www.informaworld.com/openurl?genre=article&doi=10.1080/088800101316922047&magic=pubmed. 

·  ^ "Three cases of familial hairy cell leukemia". http://cat.inist.fr/?aModele=afficheN&cpsidt=4680401. Retrieved on 2007-09-07.

·  ^ "Harrison's Principles of Internal Medicine, 16th Edition". AccessMedicine. Archived from the original on 2007-12-28. http://web.archive.org/web/20071228221145/http://www.accessmedicine.com/content.aspx?aID=65842. 

·  ^ Finding Cancer Statistics » Cancer Stat Fact Sheets »Chronic Lymphocytic Leukemia National Cancer Institute

·  ^ ColvinGA, Elfenbein GJ (2003). "The latest treatment advances for acute myelogenous leukemia". Med Health R I 86 (8): 243–6. PMID 14582219. 

·  ^ Patients with Chronic Myelogenous Leukemia Continue to Do Well on Imatinib at 5-Year Follow-Up Medscape Medical News 2006

·  ^ Updated Results of Tyrosine Kinase Inhibitors in CML ASCO 2006 Conference Summaries

·  ^ Else M, Ruchlemer R, Osuji N, et al (2005). "Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years". Cancer 104 (11): 2442–8. doi:10.1002/cncr.21447. PMID 16245328. 

·  ^ a b c d e f Wiernik, Peter H. (2001). Adult leukemias. New York: B. C. Decker. pp. 3–15. ISBN 1-55009-111-5. 

·  ^ a b Robinette, Martin S.; Cotter, Susan; Van de Water (2001). Quick Look Series in Veterinary Medicine: Hematology. Teton NewMedia. pp. 105. ISBN 1-893441-36-9. 

·  ^ Stass, Sanford A.; Schumacher, Harold R.; Rock, William R. (2000). Handbook of hematologic pathology. New York, N.Y: Marcel Dekker. pp. 193–194. ISBN 0-8247-0170-4. 

·  ^ a b c d Non-Ionizing Radiation, Part 1: Static and Extremely Low-Frequency (ELF) Electric and Magnetic Fields (IARC Monographs on the Evaluation of the Carcinogenic Risks). Geneva: World Health Organisation. 2002. pp. 332–333, 338. ISBN 92-832-1280-0. http://monographs.iarc.fr/ENG/Monographs/vol80/index.php. 

·  ^ "WHO | Electromagnetic fields and public health". http://www.who.int/mediacentre/factsheets/fs322/en/index.html. Retrieved on 2009-02-18. 

·  ^ a b c Fausel C (October 2007). "Targeted chronic myeloid leukemia therapy: seeking a cure". J Manag Care Pharm 13 (8 Suppl A): 8–12. PMID 17970609. http://www.amcp.org/data/jmcp/pages%208-12.pdf. 

·  ^ "Trends in leukemia incidence and survival in the United States (1973-1998)". http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&uid=12712476&cmd=showdetailview&indexed=google.

^ Parham, Peter (2005). The immune system. New York: Garland Science. pp. 414. ISBN 0-8153-4093-1. 
^ Hellman, Samuel; Mauch, P.M. Ed. (1999). Hodgkin's Disease. Chapter 1: Lippincott Williams & Wilkins. pp. 5. ISBN 0-7817-1502-4. 
^ a b ed. by Elaine S. Jaffe .... (2001). Pathology and Genetics of Haemo (World Health Organization Classification of Tumours S.). Oxford Univ Pr. ISBN 92-832-2411-6. 
^ www.emedicine.com on Lymphoma, Non-Hodgkin
·  ^ a b c International Myeloma Working Group (2003). "Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group". Br. J. Haematol. 121 (5): 749–57. doi:10.1046/j.1365-2141.2003.04355.x. PMID 12780789. 

·  ^ Chapel HM, Lee M (1994). "The use of intravenous immune globulin in multiple myeloma". Clin. Exp. Immunol. 97 Suppl 1: 21–4. PMID 8033429.  Full text at PMC: 1550368

·  ^ Hargreaves RM, Lea JR, Griffiths H, et al (1995). "Immunological factors and risk of infection in plateau phase myeloma" (PDF). J. Clin. Pathol. 48 (3): 260–6. doi:10.1136/jcp.48.3.260. PMID 7730490. http://jcp.bmj.com/cgi/reprint/48/3/260.  Full text at PMC: 502468

·  ^ a b Greipp PR, San Miguel J, Durie BG, et al (2005). "International staging system for multiple myeloma". J. Clin. Oncol. 23 (15): 3412–20. doi:10.1200/JCO.2005.04.242. PMID 15809451. http://jco.ascopubs.org/cgi/content/full/23/15/3412. 

·  ^ Durie BG, Salmon SE (1975). "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival". Cancer 36 (3): 842–54. doi:10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U. PMID 1182674. 

·  ^ a b c Kyle RA, Rajkumar SV (2004). "Multiple myeloma". N. Engl. J. Med. 351 (18): 1860–73. doi:10.1056/NEJMra041875. PMID 15509819. 

·  ^ Kyle, R.A., Rajkumar, S.V. (2008). "Multiple myeloma". Blood. 111 (6): 2962–2972. doi:10.1182/blood-2007-10-078022. http://bloodjournal.hematologylibrary.org/cgi/content/full/111/6/2962#F4. 

·  ^ San Miguel, J.F. et al (2008). "Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma". New England Journal of Medicine 359 (9): 906–917. doi:10.1056/NEJMoa0801479. 

·  ^ Durie, B.G.M. (2008). "Treatment of Myeloma - Are We Making Progress?". New England Journal of Medicine 359 (9): 964–966. doi:10.1056/NEJMe0805176.

^ myelodysplastic syndrome at Dorland's Medical Dictionary
^ Myelodysplastic Syndrome. The Leukemia & Lymphoma Society. White Plains, NY. 2001. p 24. Retrieved 05-12-2008.
^ Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008 Feb 1;111(3):1534-42.
^ Cazzola M, Invernizzi R, Bergamaschi G, et al (2003). "Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia". Blood 101 (5): 1996–2000. doi:10.1182/blood-2002-07-2006. PMID 12406866. 
^ Bennett JM, Catovsky D, Daniel MT, et al (August 1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". Br. J. Haematol. 33 (4): 451–8. PMID 188440. 
^ "Table 1: French-American-British (FAB) Classification of MDS". http://www.clevelandclinicmeded.com/diseasemanagement/hematology/myelo/table1.htm. 
^ Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997). "International scoring system for evaluating prognosis in myelodysplastic syndromes". Blood 89 (6): 2079–88. PMID 9058730. 
^ Bunn HF (1986). "5q- and disordered haematopoiesis". Clinics in haematology 15 (4): 1023–35. PMID 3552346. 
^ Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (1974). "Distinct haematological disorder with deletion of long arm of no. 5 chromosome". Nature 251 (5474): 437–8. doi:10.1038/251437a0. PMID 4421285. 
^ List A, Kurtin S, Roe DJ, et al (2005). "Efficacy of lenalidomide in myelodysplastic syndromes". N. Engl. J. Med. 352 (6): 549–57. doi:10.1056/NEJMoa041668. PMID 15703420. 
^ Aul C, Giagounidis A, Germing U (2001). "Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics". Int. J. Hematol. 73 (4): 405–10. PMID 11503953. 
^ Greenberg et al. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood 1997;89:2079-2088.
^ Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM (2004). "A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.". Blood 104 (2): 579–85. doi:10.1182/blood-2004-01-0338. PMID 15039286. 
^ "Centers for Medicare & Medicaid Services". http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=203. Retrieved on 2007-10-29. 
^ Wijermans P, Lübbert M, Verhoef G, et al (2000). "Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients". J. Clin. Oncol. 18 (5): 956–62. PMID 10694544. 
^ Lübbert M, Wijermans P, Kunzmann R, et al (2001). "Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine". Br. J. Haematol. 114 (2): 349–57. doi:10.1046/j.1365-2141.2001.02933.x. PMID 11529854. 
^ Silverman LR, Demakos EP, Peterson BL, et al (2002). "Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B". J. Clin. Oncol. 20 (10): 2429–40. doi:10.1200/JCO.2002.04.117. PMID 12011120. 
^ Silverman LR, McKenzie DR, Peterson BL, et al (2006). "Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B". J. Clin. Oncol. 24 (24): 3895–903. doi:10.1200/JCO.2005.05.4346. PMID 16921040. 
^ Kantarjian HM, O'Brien S, Shan J, et al (2007). "Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome". Cancer 109 (2): 265–73. doi:10.1002/cncr.22376. PMID 17133405. 
^ Kantarjian H, Issa JP, Rosenfeld CS, et al (2006). "Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study". Cancer 106 (8): 1794–803. doi:10.1002/cncr.21792. PMID 16532500. 
^ Kantarjian H, Oki Y, Garcia-Manero G, et al (2007). "Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia". Blood 109 (1): 52–7. doi:10.1182/blood-2006-05-021162. PMID 16882708. 
^ Blum W, Klisovic RB, Hackanson B, et al (2007). "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia". J. Clin. Oncol. 25 (25): 3884–91. doi:10.1200/JCO.2006.09.4169. PMID 17679729. 
^ List A, Dewald G, Bennett J, et al (2006). "Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion". N. Engl. J. Med. 355 (14): 1456–65. doi:10.1056/NEJMoa061292. PMID 17021321. 
^ "Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome". The Medical letter on drugs and therapeutics 48 (1232): 31–2. 2006. PMID 16625140. 
^ Oosterveld M, Wittebol S, Lemmens W, Kiemeney B, Catik A, Muus P, Schattenberg A, de Witte T (2003). "The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups". Br J Haematol 123 (1): 81–9. doi:10.1046/j.1365-2141.2003.04544.x. PMID 14510946. 
^ Block M, Jacobson LO, Bethard WF. Preleukemic acute human leukemia. JAMA 1953;152:1018-28. PMID 13052490
·  ^ Dameshek W (1951). "Some speculations on the myeloproliferative syndromes". Blood 6 (4): 372–5. PMID 14820991. 

·  ^ "Classification of Human Hematopoietic Malignancies". http://emice.nci.nih.gov/emice/mouse_models/organ_models/hema_models/hema_human_class. 

·  ^ Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates (2001). Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X. 

·  ^ Baxter EJ, Scott LM, Campbell PJ, et al. (2005). "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders". Lancet 365: 1054–1061. PMID 15781101. 

·  ^ James C, Ugo V, Le Couedic JP, et al. (2005). "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera". Nature 434 (7037): 1144–1148. doi:10.1038/nature03546. PMID 15793561. 

·  ^ Levine RL, Wadleigh M, Cools J, et al. (2005). "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis". Cancer Cell 7 (4): 387–397. doi:10.1016/j.ccr.2005.03.023. PMID 15837627. 

·  ^ Kralovics R, Passamonti F, Buser AS, et al. (2005). "A gain-of-function mutation of JAK2 in myeloproliferative disorders". N Engl J Med 352 (17): 1779–1790. doi:10.1056/NEJMoa051113. PMID 15858187. 

·  ^ Campbell PJ, Scott LM, Buck G, et al. (2005). "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study". Lancet 366 (9501): 1945–1953. doi:10.1016/S0140-6736(05)67785-9. PMID 16325696.

^ Maniatis A (1998). "Pathophysiology of paraprotein production.". Ren Fail 20 (6): 821–8. PMID 9834980. 
^ Apitz K. Die Paraproteinosen. Über die Störungen des Eiweißstoffwechsels bei Plasmozytomen. Virchows Arch Pathol Anat 1940;306:630-699.
^ McDevitt HO. Albert Hewett Coons. In: "Biographical Memoirs", National Academy of Sciences 1996;69:26-37. ISBN 0-309-05346-3. Fulltext.
 

^ hemoglobinopathy at Dorland's Medical Dictionary
 

·  ^ Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. pp. 625. ISBN 0-7216-0187-1. 

·  ^ Won DI, Suh JS (March 2009). "Flow cytometric detection of erythrocyte osmotic fragility". Cytometry B Clin Cytom 76 (2): 135–41. doi:10.1002/cyto.b.20448. PMID 18727072. http://dx.doi.org/10.1002/cyto.b.20448. 

·  ^ Eber S, Lux SE (April 2004). "Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer". Semin. Hematol. 41 (2): 118–41. PMID 15071790. http://linkinghub.elsevier.com/retrieve/pii/S0037196304000034. 

·  ^ Gallagher PG, Forget BG (December 1998). "Hematologically important mutations: spectrin and ankyrin variants in hereditary spherocytosis". Blood Cells Mol. Dis. 24 (4): 539–43. doi:10.1006/bcmd.1998.0217. PMID 9887280. http://linkinghub.elsevier.com/retrieve/pii/S1079-9796(98)90217-0. 

·  ^ Perrotta S, Gallagher PG, Mohandas N (October 2008). "Hereditary spherocytosis". Lancet 372 (9647): 1411–26. doi:10.1016/S0140-6736(08)61588-3. PMID 18940465. http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(08)61588-3. 

·  ^ Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ (August 2004). "Guidelines for the diagnosis and management of hereditary spherocytosis". Br. J. Haematol. 126 (4): 455–74. doi:10.1111/j.1365-2141.2004.05052.x. PMID 15287938.

^ Dresbach M (1904). "Elliptical human red corpuscles". Science 19: 469–470. doi:10.1126/science.19.481.469. PMID 17730874. 
^ Hunter, WC (1932). "Further study of a white family showing elliptical erythrocytes". Ann Intern Med 6: 775–781. 
^ Gallagher, Pg (2005). "Red cell membrane disorders." (Free full text). Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program: 13–8. doi:10.1182/asheducation-2005.1.13. PMID 16304353. http://www.asheducationbook.org/cgi/pmidlookup?view=long&pmid=16304353. 
^ Tse, Wt; Lux, Se (Jan 1999). "Red blood cell membrane disorders.". British journal of haematology 104 (1): 2–13. ISSN 0007-1048. PMID 10027705. 
^ Bannerman, Rm; Renwick, Jh (Jul 1962). "The hereditary elliptocytoses: clinical and linkage data.". Annals of human genetics 26: 23–38. ISSN 0003-4800. PMID 13864689. 
^ Hoffman, R; Benz, E, Shattil, S, Furie, B and Cohen, H (2005). Hoffman Hematology: Basic Principles and Practice (4th ed.). Philadelphia: Churchill Livingstone. ISBN 0443066280. 
^ Cattani, Ja; Gibson, Fd; Alpers, Mp; Crane, Gg (1987). "Hereditary ovalocytosis and reduced susceptibility to malaria in Papua New Guinea." (Free full text). Transactions of the Royal Society of Tropical Medicine and Hygiene 81 (5): 705–9. ISSN 0035-9203. PMID 3329776. http://www.nlm.nih.gov/medlineplus/malaria.html. 
^ Coetzer T, Lawler J, Prchal JT, Palek J (01 Sep 1987). "Molecular determinants of clinical expression of hereditary elliptocytosis and pyropoikilocytosis". Blood 70 (3): 766–72. PMID 3620700. http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=3620700. 
^ McMullin MF (1999). "The molecular basis of disorders of the red cell membrane". J. Clin. Pathol. 52 (4): 245–8. PMID 10474512. PMC: 501324. http://jcp.bmj.com/cgi/pmidlookup?view=long&pmid=10474512. 
^ Turgeon, ML (2005). Clinical Hematology: Theory and Procedures (4th ed.). Philadelphia: Lippincott Williams & Wilkins. p. 158. ISBN 0781750075. http://books.google.com/books?pg=PA158&id=cHAjsUgegpQC. 
^ Liu, S.C.; Palek, J; Nichols, PE; Derick, LH; Chiou, SS; Amato, D; Corbett, JD; Golan, DE (01 Jul 1995). "Molecular basis of altered red blood cell membrane properties in Southeast Asian ovalocytosis: role of the mutant band 3 protein in band 3 oligomerization and retention by the membrane skeleton". Blood 86 (1): 349. PMID 7795244. http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=7795244. 
^ Mgone, Cs; Koki, G; Paniu, Mm; Kono, J; Bhatia, Kk; Genton, B; Alexander, Nd; Alpers, Mp (May 1996). "Occurrence of the erythrocyte band 3 (AE1) gene deletion in relation to malaria endemicity in Papua New Guinea.". Transactions of the Royal Society of Tropical Medicine and Hygiene 90 (3): 228–31. ISSN 0035-9203. PMID 8758056. 
·  ^ Hirokawa M, Sawada K, Fujishima N, et al (January 2008). "Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group". Haematologica 93 (1): 27–33. doi:10.3324/haematol.11655. PMID 18166782. http://www.haematologica.org/cgi/pmidlookup?view=long&pmid=18166782. 

·  ^ Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES (December 2000). "Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature". Clin Transplant 14 (6): 586–91. PMID 11127313. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0902-0063&date=2000&volume=14&issue=6&spage=586. 

·  ^ Kwong YL, Wong KF (1998). "Association of pure red cell aplasia with T large granular lymphocyte leukaemia". J. Clin. Pathol. 51 (9): 672–5. PMID 9930071. PMC: 500904. http://jcp.bmj.com/cgi/pmidlookup?view=long&pmid=9930071. 

·  ^ Three episodes of acquired pure red cell aplasia restricted to pregnancy. Miller AC, Rashid RM. J Perinat Med. 2008;36(3):270-1.

·  ^ Bennett CL, Luminari S, NissensonAR, et al (2004). "Pure red-cell aplasia and epoetin therapy". N. Engl. J. Med. 351 (14): 1403–8. doi:10.1056/NEJMoa040528. PMID 15459301. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15459301&promo=ONFLNS19. 

·  ^ Sawada K, Hirokawa M, Fujishima N, et al (August 2007). "Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group". Haematologica 92 (8): 1021–8. PMID 17640861. http://www.haematologica.org/cgi/pmidlookup?view=long&pmid=17640861. 

·  ^ Sawada K, Fujishima N, Hirokawa M (August 2008). "Acquired pure red cell aplasia: updated review of treatment". Br. J. Haematol. 142 (4): 505–14. doi:10.1111/j.1365-2141.2008.07216.x. PMID 18510682. PMC: 2592349. http://dx.doi.org/10.1111/j.1365-2141.2008.07216.x.

·  ^ absolute polycythemia at Dorland's Medical Dictionary

·  ^ relative polycythemia at Dorland's Medical Dictionary

·  ^ Polycythemia vera nlm.nih.gov

·  ^ Jacques Wallach; Interpretation of Diagnostic Tests, 7th Ed.; Lippencott Williams & Wilkins

·  ^ Current Medical Diagnosis & Treatment 2008, p. 438; McGraw Hill Lange

·  ^ Niu X, Miasnikova GY, Sergueeva AI, et al (February 2009). "Altered cytokine profiles in patients with Chuvash polycythemia". Am. J. Hematol. 84 (2): 74–8. doi:10.1002/ajh.21327. PMID 19062180. http://dx.doi.org/10.1002/ajh.21327.